Gaucher Disease Type 1 Carries 12% Parkinson Risk by Age 80

Quantifying Neurodegenerative Risk in Glucocerebrosidase Deficiency

Pathogenic variants in the glucocerebrosidase gene (GBA1) are the most common genetic risk factor for Parkinson disease, conferring an odds ratio of 5.43 for carriers compared to non-carriers [1, 2]. While biallelic GBA1 mutations cause Gaucher disease, a lysosomal storage disorder, even heterozygous carriers face a higher incidence of cognitive and motor dysfunction [3, 4]. This link is thought to involve a bidirectional mechanism where reduced glucocerebrosidase activity promotes the aggregation of alpha-synuclein, a key protein implicated in synucleinopathies [5, 6, 7]. Despite this established association, the lifetime penetrance of parkinsonism in patients with Gaucher disease has remained unclear. A new longitudinal analysis of 1,618 patients from a global registry provides greater clarity, reporting an age-specific Parkinson disease prevalence of 12.2% by age 80 [8].

Longitudinal Tracking of Motor and Nonmotor Phenotypes

To better define this risk, researchers analyzed data from the International Collaborative Gaucher Group Gaucher Registry, a global database containing records for 1,618 patients with Gaucher disease type 1 (GD1) as of February 2024. The longitudinal study design allowed for tracking the clinical progression of these patients over time to identify the emergence of neurodegenerative complications. The investigators collected data on formal clinical diagnoses of Parkinson disease and dementia with Lewy bodies. They also monitored for specific motor signs, including rest tremor and falls, and a range of nonmotor symptoms such as cognitive impairment, REM sleep behavior disorder, loss of sense of smell, and autonomic dysfunction (the impairment of involuntary bodily functions like blood pressure regulation).

Recognizing that previous penetrance estimates may have been low due to underdiagnosis, the study employed two distinct case definitions. The first was a conservative measure based strictly on a physician-confirmed diagnosis of Parkinson disease or dementia with Lewy bodies. The second was a more liberal definition of possible parkinsonian syndrome (pPS), designed to capture a broader spectrum of neurodegeneration. A patient was classified as having pPS if they had at least two of the tracked signs or symptoms, or a formal diagnosis of Parkinson disease or dementia with Lewy bodies. The date of pPS onset was set as the earliest report of a second symptom or a formal diagnosis.

To quantify risk over time, the researchers estimated the age-specific prevalence of both conditions using Kaplan-Meier survival curves, a statistical method that calculates the probability of an event occurring over a specified period. This approach allowed the authors to model how the risk of neurodegeneration accumulates as patients with Gaucher disease type 1 age. The inclusion of the broader pPS category was critical for capturing early or atypical presentations of movement disorders that might not yet meet the full diagnostic criteria for Parkinson disease.

Age-Specific Prevalence and Symptom Penetrance

The analysis of 1,618 patients revealed a significant cumulative risk of neurodegeneration with advancing age. By 80 years, the prevalence of formally diagnosed Parkinson disease reached 12.2% (95% CI, 8.8% to 16.8%). This finding translates to a clinical reality where approximately one-in-nine patients with Gaucher disease type 1 will be diagnosed with Parkinson disease by their eighth decade. These data provide a concrete statistical framework for counseling patients about their long-term neurological risks, clarifying that while the risk is substantially elevated, the majority of patients will not develop the condition.

However, when the researchers applied the broader criteria for possible parkinsonian syndrome, the estimated disease burden increased substantially. By age 80, the prevalence of pPS was 21.4% (95% CI, 17.1% to 26.6%). This indicates that more than one-in-five patients were diagnosed with Parkinson disease, dementia with Lewy bodies, or experienced significant movement disorder symptoms by that age. The higher prevalence of pPS suggests that a considerable portion of the Gaucher disease type 1 population exhibits neurological signs that may precede or fall outside of a formal Parkinson disease diagnosis, underscoring the need for vigilant longitudinal monitoring for tremors, falls, and cognitive changes in clinical practice.

Genotype Variations and Enzymatic Activity

The risk of neurodegeneration in Gaucher disease type 1 appears to vary with specific GBA1 mutations, though not in a simple dose-dependent manner. Among the 100 patients with two severe GBA1 variants, the Parkinson disease prevalence was 10.9% (95% CI, 4.3% to 26.1%) by age 80. In comparison, the 371 patients with one mild and one severe variant had a Parkinson disease prevalence of 14.3% (95% CI, 8.4% to 23.6%) by the same age. For the 641 patients with two mild variants, the prevalence was 11.2% (95% CI, 6.7% to 18.3%). These figures suggest that while all genotypes confer elevated risk, the specific mutation pairing subtly influences the statistical probability of developing parkinsonism.

A clinically important observation from the registry data is that patients with two severe GBA1 variants had a qualitatively lower prevalence of both Parkinson disease and possible parkinsonian syndrome compared to patients with at least one mild variant. This finding challenges the straightforward hypothesis that lower enzyme levels directly predict higher neurodegenerative risk. The data demonstrate that most patients remain free of Parkinson disease despite having very low residual acid ß-glucosidase activity, the enzyme deficient in Gaucher disease. This suggests that while enzyme deficiency is a critical factor, it does not solely determine the risk of developing Parkinson disease, pointing to the involvement of other genetic or environmental modifiers.

Clinical Implications for Neurological Surveillance

These findings from a large cohort of 1,618 patients help establish a framework for the long-term neurological management of Gaucher disease type 1. However, clinicians should consider the study's demographics when applying the results. The authors note that most patients were from North America and Europe, meaning the generalizability of these specific prevalence rates to other global regions is unknown. Genetic or environmental factors unique to other populations were not captured in this dataset and could alter risk profiles.

For the practicing physician, the high cumulative incidence of neurological signs necessitates proactive surveillance in aging patients with Gaucher disease. The study tracked key motor signs like rest tremor and falls, as well as nonmotor symptoms such as cognitive impairment, REM sleep behavior disorder (a condition where patients physically act out vivid dreams), loss of sense of smell, and autonomic dysfunction. Given that more than one-in-five patients developed Parkinson disease, dementia with Lewy bodies, or experienced related symptoms by age 80, routine screening for these prodromal markers is clinically justified. Early identification may facilitate timely interventions and better prepare patients for the potential neurodegenerative course affecting a significant minority of this population.

References

1. Sidransky E, Nalls MA, Aasly J, et al. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. New England Journal of Medicine. 2009. doi:10.1056/nejmoa0901281

2. Do J, McKinney CE, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Molecular Neurodegeneration. 2019. doi:10.1186/s13024-019-0336-2

3. Beavan M, McNeill A, Proukakis C, Hughes D, Mehta A, Schapira AH. Evolution of Prodromal Clinical Markers of Parkinson Disease in aGBAMutation–Positive Cohort. JAMA Neurology. 2014. doi:10.1001/jamaneurol.2014.2950

4. Aharon‐Peretz J, Rosenbaum H, Gershoni‐Baruch R. Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews. New England Journal of Medicine. 2004. doi:10.1056/nejmoa033277

5. Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. Molecular Neurodegeneration. 2021. doi:10.1186/s13024-021-00501-z

6. Chiasserini D, Paciotti S, Eusebi P, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies. Molecular Neurodegeneration. 2015. doi:10.1186/s13024-015-0010-2

7. Gatto E, Prat GDD, Etcheverry J, Drelichman G, Cesarini M. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. Brain Science. 2019. doi:10.3390/brainsci9020030

8. Alcalay RN, Mistry P, Fonzo AD, et al. Age-Specific Parkinson Disease Risk in Gaucher Disease Type 1: Data From the ICGG Gaucher Registry.. Neurology. 2026. doi:10.1212/WNL.0000000000214986